June 5, 2018 / 5:19 AM / 6 months ago

BRIEF-Basilea Pharmaceutica Presents Phase 1 Clinical Data With Anticancer Drug Candidate Bal101553

June 5 (Reuters) - BASILEA PHARMACEUTICA AG:

* REPORTS PRESENTATION OF PHASE 1 CLINICAL DATA WITH ANTICANCER DRUG CANDIDATE BAL101553 AT ASCO MEETING

* BASILEA - DRUG CANDIDATE SHOWED INITIAL SIGNALS OF CLINICAL ACTIVITY AS MONOTHERAPY AND ACCEPTABLE SAFETY PROFILE SUPPORTING ITS ADVANCEMENT INTO PHASE 2A CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below